1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
ReNeuron Group plc

ReNeuron Group plc

RNUGF
ReNeuron Group plcUS flagOther OTC
0.00
USD
- -
- -
62,891.00Market Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
Revenue per Share
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
0.19
0.01
0.01
0.01
Basic EPS, GAAP
-1.1
-0.88
-0.83
-0.48
-0.48
-0.42
-0.48
-0.54
-0.44
-0.35
-0.29
-0.17
-0.09
Free Cash Flow per Basic Share
-0.93
-0.82
-0.78
-0.41
-0.47
-0.44
-0.39
-0.46
-0.37
-0.44
-0.15
-0.13
-0.13
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-5.44
-5.14
-5.1
-2.44
-2.41
-1.54
-1.71
-3.19
-3.58
-3.89
-3.51
-2.57
-2.65
Tangible Book Value per Share
1.74
0.56
0.47
1.4
0.63
2.47
1.64
1.12
0.71
0.4
0.48
0.17
0.09
Basic Weighted Avg Shares
6
7
8
15
18
27
33
33
33
33
39
57
57
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
6
- -
- -
1
Operating Margin (%)
-22,986.21
-17,210
-41,694.12
-36,222.73
-34,646.67
-47,324.14
-43,232.61
-49,372.09
-38,977.55
-239.23
-5,054.47
-2,785.36
-1,342.45
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-6
-6
-6
-7
-9
-11
-16
-18
-14
-11
-11
-10
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-21,200
-15,572.5
-37,323.53
-32,118.18
-29,686.67
-39,151.72
-33,854.35
-40,965.12
-29,281.63
-188.16
-4,415.18
-2,404.22
-1,020.38
Working Capital
9
4
3
20
12
61
52
36
23
13
19
9
5
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
- -
- -
Total Equity
11
5
5
22
13
68
53
37
23
13
19
10
5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
53.23%
-26.62%
-48.86%
Free Cash Flow
7.11%
-6.85%
0.99%
Net Income, GAAP
1.68%
-19.67%
-44.18%
Sales/Revenue/Turnover
1,239.86%
2,456.81%
31.51%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.17
2023
- -
- -
- -
- -
-0.09
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Iain Gladstone Ross
Full Time Employees
26
Sector
Healthcare
Industry
Biotechnology
Address
Pencoed Business Park Pencoed United Kingdom CF35 5HY
IPO Date
Apr 12, 2007
Website
reneuron.com
Similar Companies
Bavarian Nordic A/S (BAVA.CO)
BINEX Co., Ltd. (053030.KQ)
MorphoSys AG (MOR.DE)
Haleos Labs Limited (HALEOSLABS.BO)
Medicenna Therapeutics Corp. (MDNA)
Lixte Biotechnology Holdings, Inc. (LIXT)
Business
ReNeuron Group plc is a biotechnology firm dedicated to advancing next-generation drug delivery systems and offering specialized cell lines. Following its exit from administration in March 2025, the company has successfully re-established itself as a private entity, with its shares no longer publicly traded. ReNeuron now primarily focuses on its CustomEX™ platform, which harnesses the natural attributes of exosomes derived from engineered stem cells to facilitate targeted drug delivery. This innovative platform is designed to overcome existing barriers in delivering complex therapeutic modalities, including siRNA, mRNA, and gene editing complexes, to specific tissues such as the central nervous system, lungs, and kidneys. Beyond its CustomEX™ technology, ReNeuron also generates revenue through the out-licensing of its extensive catalogue of established, immortalized stem cell lines for research and development purposes. The company's prior clinical-stage programs, including CTX for stroke disability and human retinal progenitor cell therapy for retinitis pigmentosa, have been strategically out-licensed to Fosun Pharma. Founded in 1997, the company has since relocated its main headquarters to Weybridge, Surrey, in the United Kingdom.

Company News

APIChat